Kazia Therapeutics - Doubling down on clinical development
Kazia Therapeutics’ FY22 results recapped a busy year focused on strengthening its oncology-focused pipeline. While the year was marked by...
691 Views
Kazia Therapeutics - Ambiguity in GBM but pipeline still busy
Kazia Therapeutics has reported that the company’s lead asset paxalisib (PI3K/mTOR inhibitor) has not graduated to Stage 2 of the Phase III GBM...
685 Views
Kazia Therapeutics - Paxalisib awarded RPDD in AT/RT
Kazia Therapeutics has announced that the company’s brain-penetrant kinase inhibitor, paxalisib, has been granted Rare Pediatric Disease...
685 Views
Kazia Therapeutics - Paxalisib receives ODD for AT/RT
In an encouraging development for Kazia Therapeutics’ efforts towards combating pediatric brain cancers, its lead drug paxalisib has received...
688 Views
Kazia Therapeutics - Deep dive into childhood brain cancer
In light of the positive newsflow from Kazia’s efforts in addressing adult brain cancer, management is leveraging its niche expertise and...
694 Views